MUROMACHI CHEMICALS INC.
4885・Standard Market・Pharmaceuticals
Governance
Company with an Audit and Supervisory Committee. The Board of Directors consists of 9 members in total: 6 directors (1 outside) and 3 Audit and Supervisory Committee members (all outside). The outside director ratio is approximately 44% (4 out of 9 members). A Nomination and Compensation Committee (with outside officers holding a majority) has been established as an advisory body to the Board of Directors to ensure transparency and independence in governance.
Risk Management
The Company has established a Risk Management Committee chaired by the President and Representative Director, which meets once a month (on the same day as the Management Meeting). The committee shares and discusses risk information from each department and determines response policies for company-wide risks. The Company has formulated a Business Continuity Strengthening Plan and obtained certification from the Small and Medium Enterprise Agency. A system has been established to set up an emergency response headquarters in the event a risk materializes.
Shareholder Returns
Annual dividend for FY2026 (ending May 2026) is ¥26 per share (interim ¥10 + year-end ¥16), total dividends of ¥104 million, payout ratio of 64.1%. For FY2027 (ending May 2027), an annual dividend of ¥26 (interim and year-end ¥13 each) is planned, with an expected payout ratio of 29.8%. Share buybacks can be flexibly implemented by resolution of the Board of Directors.
Dividend Policy
The basic policy is to pay stable dividends, comprehensively taking into account business performance, payout ratio, and internal reserves. For FY2026 (ending May 2026), an interim dividend of ¥10 and a year-end dividend of ¥16 were implemented, for an annual total of ¥26 (payout ratio of 64.1%). For FY2027 (ending May 2027), an annual dividend of ¥26 (interim and year-end ¥13 each, expected payout ratio of 29.8%) is planned. The company operates a system of dividends paid twice a year, with the interim dividend determined by resolution of the Board of Directors and the year-end dividend by resolution of the General Meeting of Shareholders. The Articles of Incorporation stipulate that share buybacks can be flexibly implemented by resolution of the Board of Directors.
ESG
With "Health" and "Environment" as its purpose, the company promotes sustainability initiatives centered on human capital development and internal workplace environment improvement. It has set targets of an annual paid leave utilization rate of 80% or higher, a ratio of women in management positions of 10% or higher by FY2028 (ending March 2028), and obtaining certification as an Excellent Health Management Corporation. Results for the fiscal year under review were a paid leave utilization rate of 77% and a ratio of women in management positions of 9.8%. Quantitative disclosure related to climate change has not been made at this time.
Last updated: August 26, 2025